|| Checking for direct PDF access through Ovid
Cystic fibrosis (CF) is a life-shortening disease arising as a consequence of mutations within theCFTRgene. Novel therapeutics for CF are emerging that target CF transmembrane conductance regulator protein (CFTR) defects resulting from specificCFTRvariants. Ivacaftor is a drug that potentiates CFTR gating function and is specifically indicated for CF patients with a particularCFTRvariant,G551D-CFTR(rs75527207). Here, we provide therapeutic recommendations for ivacaftor based on preemptiveCFTRgenotype results.